Tuesday, September 23, 2014 11:39:45 AM
The researchers in India will be planning and executing a comprehensive research program which would not be possible for several months to a year in Canada due to the waiting period for obtaining a Canadian R and D license. They will also prepare protocols for clinical trials which can be conducted immediately in India and subsequently in Canada after Verde obtains its R and D license. The company plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments such as chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others.
"This new Research and Development Program with a focus on developing custom formulations for specific medical issues will firmly place Verde on the cutting edge of cannabinoid and THC technology in treating illness, and our association with our new Indian partner will enable us to become a clearing house for research into new applications for marijuana based treatments of a variety of illnesses. The Verde brand will be synonymous with innovation into natural based remedies for a variety of debilitating illnesses." stated Mr. Sangha.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM